Table of Contents
Spatial transcriptomic analysis of primary and recurrent adult-type granulosa cell ovarian tumors identifies possible therapeutic targets
Background: Adult-type granulosa cell tumors (AGCT) are an uncommon ovarian cancer subtype. We used spatial transcriptomics to explore gene expression in tumor versus adjacent stromal cells within the tumor microenvironment (TME), and in primary ...
More.Background: Adult-type granulosa cell tumors (AGCT) are an uncommon ovarian cancer subtype. We used spatial transcriptomics to explore gene expression in tumor versus adjacent stromal cells within the tumor microenvironment (TME), and in primary versus recurrent tumors.
Methods: Four unmatched FFPE AGCT samples (two primary, two recurrent) were processed on the 10X Genomics Visium platform. Seurat clusters and STdeconvolution topics were annotated, followed by pathway enrichment and TME assessment by functional gene signatures. Primary and recurrent tumors were compared using pseudobulk and DESeq2. Tumor-stromal interactions were analyzed with SpatialCellChat, and trajectories with Monocle.
Results: Granulosa cells and fibroblasts were the most common cell types. These were subclassified into proliferative and steroidogenic granulosa cells, and myofibroblastic (myCAF), extracellular matrix (ECM-CAF), inflammatory (iCAF), and perivascular fibroblasts. MAPK, PI3K, and KRAS signaling were the most frequently enriched pathways. The TME was fibrotic and dominated by cancer-associated fibroblasts. SpatialCellChat highlighted the importance of the extracellular matrix and showed bidirectional tumor-stroma signaling. In total, 122 genes were upregulated in primary tumors and 33 were differentially expressed in recurrent tumors, including the steroidogenic enzyme CYP19A1, the receptor tyrosine kinases ERBB4 and RASGRF1, and stromal remodeling genes.
Conclusion: Spatial transcriptomics demonstrates hormonally active tumor regions and a fibrotic, CAF-dominant tumor microenvironment in AGCT. Several findings with potential translational significance could warrant further investigation.
Less.Sarah McDonald, ... Elizabeth E. Hopp
DOI:https://doi.org/10.70401/EXO.2026.0024 - November 17, 2026
Metabolic regulations by p53 in tumour suppression: From cell-intrinsic homeostasis to microenvironmental control
The transcription factor p53, widely known as the “guardian of the genome”, is a central tumour suppressor that coordinates cellular responses to stress. Upon DNA damage and other perturbations, p53 activates transcriptional programs that promote cell-cycle ...
More.The transcription factor p53, widely known as the “guardian of the genome”, is a central tumour suppressor that coordinates cellular responses to stress. Upon DNA damage and other perturbations, p53 activates transcriptional programs that promote cell-cycle arrest, senescence, and apoptosis. However, it has become increasingly clear that these canonical pathways alone do not fully account for the tumour-suppressive functions of p53. A growing body of evidence instead highlights metabolic regulation as a major component of the p53 network. p53 coordinates cellular metabolism to preserve genomic and redox homeostasis, regulate adaptation to metabolic stress, and influence cell-fate decisions through multiple forms of regulated cell death. Beyond cell-intrinsic effects, p53-dependent metabolic programs also shape the tumour microenvironment by modulating nutrient availability, immune-cell function, and intercellular signalling. In this review, we discuss how p53 regulates metabolism at both cell-intrinsic and cell-extrinsic levels and how these functions contribute to tumour suppression. We further examine how distinct p53 mutations reprogram metabolic pathways and alter the tumour-suppressive activities of wild-type p53, emphasizing the context dependence and functional heterogeneity of mutant p53. Together, these findings position metabolic regulation as a central and multifaceted component of p53 biology with important implications for understanding tumour development and therapeutic vulnerability.
Less.Stephanie Gurres, ... Ivano Amelio
DOI:https://doi.org/10.70401/EXO.2026.0023 - October 28, 2026
Radical-mediated C7 cholesterol oxidation during erastin-induced ferroptosis
Aims: Ferroptosis is driven by iron-dependent lipid peroxidation, but whether cholesterol undergoes radical-mediated oxidation during this process remains incompletely understood. We examined the temporal relationship between lipid peroxidation, ...
More.Aims: Ferroptosis is driven by iron-dependent lipid peroxidation, but whether cholesterol undergoes radical-mediated oxidation during this process remains incompletely understood. We examined the temporal relationship between lipid peroxidation, cell death, and C7 cholesterol oxidation during erastin-induced ferroptosis.
Methods: Human SH-SY5Y cells were treated with erastin. Cell viability, lipid hydroperoxides, and lipid radicals were assessed using Alamar Blue, Liperfluo, and LipiRADICAL, respectively. Total 7α-hydroxycholesterol (t7α-OHCh), total 7β-hydroxycholesterol (t7β-OHCh), and 7-ketocholesterol (7-ketoCh) were quantified by gas chromatography–mass spectrometry (GC–MS) after triphenylphosphine reduction and saponification.
Results: Erastin-induced cell death was suppressed by deferoxamine, ferrostatin-1, and α-tocopherol. Liperfluo fluorescence increased before detectable LipiRADICAL fluorescence and loss of cell viability. t7α-OHCh increased during the early phase, whereas t7β-OHCh increased later; no statistically significant change in 7-ketoCh was detected. Because t7α-OHCh and t7β-OHCh represent composite pools of pre-existing free and esterified hydroxycholesterols and hydroperoxide-derived products, the early t7α-OHCh signal cannot distinguish enzymatic hydroxylation from a 7α-hydroperoxycholesterol (7α-OOHCh)-derived product. The increase in t7β-OHCh together with the overall C7 stereochemical profile is consistent with radical-mediated C7 cholesterol oxidation.
Conclusion: These findings support radical-mediated C7 cholesterol oxidation as an early component of erastin-induced ferroptotic lipid damage. The biological activity and extracellular transfer of these products remain to be established.
Less.Yuta Akiba, ... Yoshiro Saito
DOI:https://doi.org/10.70401/EXO.2026.0022 - October 28, 2026
Beyond slides: The era of 3D histology
Histology has long served as the foundation of tissue diagnosis, yet its reliance on thin two-dimensional (2D) sections incompletely captures the spatial continuity, volumetric heterogeneity, and multicellular architecture of biological tissues. Recent ...
More.Histology has long served as the foundation of tissue diagnosis, yet its reliance on thin two-dimensional (2D) sections incompletely captures the spatial continuity, volumetric heterogeneity, and multicellular architecture of biological tissues. Recent advances in volumetric imaging, spatial omics, label-free optical pathology, and artificial intelligence are enabling tissue analysis beyond the conventional glass slide. In this Perspective, we discuss the emergence of three-dimensional (3D) histology and the technological developments driving the transition from planar sampling to volumetric tissue analysis. We highlight how the added spatial dimension can reveal diagnostically relevant features that are only partially represented in conventional sections, and discuss efforts to extend molecular profiling into intact tissues through multiplexed imaging and volumetric spatial omics. We further examine the growing role of label-free modalities, particularly stimulated Raman scattering microscopy, for rapid and minimally destructive pathology. Finally, we consider the computational foundations required to reconstruct, align and interpret volumetric data, including emerging applications in virtual histology and molecular prediction. Together, these developments suggest that 3D histology is evolving into a broader framework for integrating tissue morphology, molecular state, and function within intact spatial contexts, with emerging opportunities for biological discovery and precision medicine.
Less.Zihang He, ... Lixue Shi
DOI:https://doi.org/10.70401/EXO.2026.0021 - September 30, 2026